(Q29938523)

English

ABL1 BCR::ABL H396R

genetic variant

H396R
RS121913454
H415R
HIS396ARG
HIS415ARG
BCR-ABL H396R
BCR-ABL HIS415ARG
BCR-ABL HIS396ARG
BCR-ABL H415R
BCR-ABL1 H396R
BCR-ABL1 HIS396ARG
BCR::ABL H396R

In more languages

default values for all languages

No label defined

No description defined

Statements

missense mutation

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

transcript fusion

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

human chromosome 9

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

133750356

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

133750356

genomic assembly

Genome assembly GRCh37

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

biological variant of

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

positive therapeutic predictor for

medical condition treated

chronic myeloid leukemia

1 reference

12 July 2017

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Overriding imatinib resistance with a novel ABL kinase inhibitor

https://civic.genome.wustl.edu/links/evidence/4414

https://civic.genome.wustl.edu/links/evidence/4413

https://civic.genome.wustl.edu/links/evidence/4416

https://civic.genome.wustl.edu/links/evidence/4415

https://civic.genome.wustl.edu/links/evidence/4412

medical condition treated

chronic myeloid leukemia

1 reference

12 July 2017

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

Overriding imatinib resistance with a novel ABL kinase inhibitor

https://civic.genome.wustl.edu/links/evidence/4411

https://civic.genome.wustl.edu/links/evidence/4410

https://civic.genome.wustl.edu/links/evidence/4409

negative therapeutic predictor for

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2687

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4411

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

dasatinib monohydrate

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4413

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

imatinib mesylate

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6258

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4410

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

imatinib mesylate

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/6988

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/4417

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

dasatinib monohydrate

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

chronic myeloid leukemia

statement disputed by

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/7823

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

chronic myeloid leukemia

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/evidence/2688

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Identifiers

CIViC variant ID

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

dbSNP Reference SNP number

1 reference

HGVS nomenclature

NM_005157.5:c.1187A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

NP_005148.2:p.His396Arg

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

NC_000009.11:g.133750356A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

ENST00000318560.5:c.1187A>G

1 reference

28 March 2022

https://civic.genome.wustl.edu/links/variants/1030

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29938523&oldid=2014804910"